Expressions and clinical significances of Runx3 and CHD5 in colorectal cancer
10.3760/cma.j.issn.1673-422X.2016.05.008
- VernacularTitle:Runx3和CHD5基因在结直肠癌中的表达及临床意义
- Author:
Dong MA
;
Xuejun SUN
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Pathology,clinical;
ROC curve;
Runx3;
CHD5
- From:
Journal of International Oncology
2016;43(5):350-355
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expressions and clinical significances of Runt-domain-related 3 (Runx3) and chromodomain helicase DNA-binding protein 5 (CHD5) in colorectal cancer.Methods Ninety-six colorectal cancer tissue samples and matched adjacent normal tissues and 72 colorectal adenoma tissues were collected.Real-time quantitative polymerase chain reaction (qRT-PCR) and Western blotting were used to detect the mRNA and protein expression of Runx3 and CHD5.The associations of Runx3 and CHD5 expression with clinical pathological characteristics,diagnostic value and prognosis relationship of patients were further analyzed.Results Runx3 and CHD5 relative expressions of mRNA and protein were 0.35 ± 0.00,0.28 ± 0.02 and 0.26 ± 0.02,0.31 ± 0.01,which were significantly lower than those in the matched adjacent tissues 0.95 ± 0.02,0.92 ± 0.02 and 0.89 ± 0.03,0.93 ± 0.02 (t =2.36,P ＜ 0.05;t =1.25,P ＜ 0.05;t =1.37,P ＜ 0.05;t =1.13,P ＜ 0.05) and colorectal adenoma tissues 0.89 ± 0.02,0.90 ± 0.02 and 0.85±0.02,0.87±0.04 (t=2.27,P＜0.05;t=2.16,P＜0.05;t=1.25,P＜0.05;t=2.65,P＜0.05).Runx3 and CHD5 expressions differed significantly between tumors with different TNM stages (x2 =4.65,P =0.031;x2 =7.89,P =0.005),depths of tumor invasion (x2 =4.17,P =0.041;x2 =4.86,P =0.028),lymph node statuses (x2 =4.20,P =0.040;x2 =7.02,P =0.008),or histological differentiation (x2 =7.31 P =0.036;x2 =9.54,P =0.023).Linear correlation analysis showed that the expressions of the two genes were positively correlated (r =0.572,P =0.001).Receiver operating characteristic (ROC) curve showed that Runx3 and CHD5 had diagnostic value (AUC were 0.712,0.745;sensitivity and specificity were 45.9％,52.5％ and 83.6％,81.4％ respectively).Runx3 and CHD5 both low expression group compared with the other patient groups in overall survival time (x2 =8.156,P ＜ O.05) and progression-free survival (x2 =6.325,P ＜ 0.05) had statistically significant differences.Conclusion Runx3 and CHD5 are low expressed in colorectal cancer and may prove useful as biomarkers for diagnosis target and prognostic indication in patients with colorectal cancer.
